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OBJECTIVES: The objectives of the current analysis are: 1) to update cost-effective-
ness estimates for the current 4 dose schedule of 7-valent pneumococcal conjugate 
vaccine (PCV7) using recent 2008 epidemiological data and new data obtained from 
recent resource use for pneumococcal disease; 2) to investigate the cost-effectiveness 
of a reduced-dose schedule, and switching to 10- or 13-valent pneumococcal vaccines. 
METHODS: We constructed a decision analysis model to compare the expected net 
costs and health beneﬁts in two hypothetical cohorts of 180,000 children—one vacci-
nated (with the PCV7/PCV10/PCV13) and one unvaccinated. Both herd protection 
and serotype replacement were included for the cohorts, no net-vaccine beneﬁts for 
adults and elderly were included. RESULTS: Under base-case assumptions vaccination 
with 4-doses of PCV7 prevents 72 cases of invasive pneumococcal disease and 6,801 
cases of respiratory infections corresponding to a gain of 173 discounted life-years 
or a gain of 270 QALYs. The cost savings due to vaccination is estimated at a2.7 
million annually. With a vaccine price of a50, the cost-effectiveness ratio is estimated 
a116,847/QALY or a182,002/LYG. Using a 3-dose schedule lowers the CER to 
a85,104/QALY gained. At a threshold of a20,000/QALY switching from the 4-dose 
PCV7 schedule to PCV10 or PCV13 could be cost-effective with an aggregated vacci-
nation cost below a219.76 or a240.64 for the PCV10 and PCV13, respectively. Costs 
savings is reached below a205.28 or a210.88. CONCLUSIONS: Current routine 
vaccination with four doses of PCV7 exhibits relatively high cost-effectiveness ratios 
due to present rapid increase of non-vaccine serotype disease in vaccinated children 
and absence of herd effects in unvaccinated individuals. Cost-effectiveness can be 
improved using reduced dose schedules. In the presence of pneumococcal vaccination, 
switching to the PCV10 or PCV13 seems health economically justiﬁed at limited price 
increases.
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OBJECTIVES: Herpes zoster (HZ) is a common health problem causing signiﬁcant 
pain and morbidity especially in the older population. A new vaccine preventing HZ 
and its main complication, post-herpetic neuralgia (PHN) has demonstrated its efﬁcacy 
in reducing the incidence, severity and duration of the HZ pain. The objective of this 
study was to evaluate the cost-effectiveness of a vaccination policy against HZ and 
PHN in Germany for the population aged 60 and above. METHODS: An existing 
European core Markov model was adapted to assess the lifetime clinical and economic 
impact of a HZ vaccination policy compared to the current situation of no vaccination 
policy in Germany. As outcome parameters, costs per QALY, costs per HZ and PHN 
case avoided are considered. Transition probabilities between the various health states 
and effectiveness data are derived from published literature and adapted to Germany 
where necessary. Epidemiological and cost data (reference year 2008) are calculated 
for Germany considering a societal and a third party payer perspective. Deterministic 
and probabilistic sensitivity analyses were performed. RESULTS: From the third party 
payer perspective, ICERs of the vaccination programme against HZ and PHN were 
a20,139 per QALY gained, a1,653 per HZ case avoided, and a11,489 per PHN case 
avoided. The number needed to vaccinate (NNV) to avoid one case of HZ and PHN 
is 12 and 86, respectively. Deterministic sensitivity analyses show that results are inter 
alia sensitive to the duration of vaccine protection, incidence of HZ and PHN and 
discount rates. Probabilistic sensitivity analyses conﬁrm the cost-effectiveness of the 
vaccination policy. CONCLUSIONS: Implementing an HZ vaccination policy in the 
German population aged 60 years and above seems to be cost-effective and offers 
substantial health beneﬁts by avoiding HZ and PHN cases at reasonable costs.
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OBJECTIVES: We aimed to determine the cost-effectiveness of atosiban compared to 
betamimetics in the treatment of preterm labour in Austria. METHODS: A systematic 
literature review identiﬁed RCTs comparing atosiban to betamimetics in the ﬁrst 48 
hours of hospitalisation. In Austria hexoprenaline is the most common betamimetic 
indicated for preterm labour, and previous research had demonstrated comparable 
safety proﬁles within this group. Cost-minimisation analysis was conducted using 
Excel model of the combined ITT population. Drug dosing was based on clinical trial 
protocols and Austrian treatment guidelines. Costs of drugs were obtained for 2009. 
The Hospital Financing System (LKF) score was calculated using the 2009 Kdok 
software. Analyses were conducted from the payer (KRAZAF) and hospital (KAV) 
perspectives. RESULTS: Six RCTs were identiﬁed: three double-blinded, one single-
blinded, and two open label studies. Meta-analysis of the double blinded studies 
showed, that atosiban and betamimetics had similar efﬁcacy (RR  0.99, 95%CI:0.94–
1.04, p  0.772) in preventing preterm labour for 48 hours. Atosiban was associated 
with a signiﬁcantly lower frequency of adverse events for tachycardia, palpitation, 
vomiting, headache, hyperglycaemia, tremor, dyspnoea, chest pain, hypocalemia and 
foetal tachycardia (p  0.05). From the public payer perspective, the cost saving from 
choosing atosiban over hexoprenaline was a323 per patient. From the hospital per-
spective, savings ranged from a807 for 18 hours of tocolysis to a721 for 48 hours. 
The results were consistent when the double-blinded clinical trials were analysed sepa-
rately or combined with the single-blinded and open label trials, and were robust in 
the probabilistic sensitivity analysis, where cost savings were achieved in 83–100% of 
bootstrapped cases. The switch from hexoprenaline to atosiban would lead to savings 
ranging from 41% to 83%. CONCLUSIONS: Atosiban is cost saving versus betami-
metics in the treatment of preterm labour in Austria from both the payer and hospital 
perspectives. Cost savings result from the superior safety proﬁle of atosiban.
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OBJECTIVES: PRINEO* is a safe and effective alternative to standard of care (SOC) 
suture techniques for wound closure. This study evaluated differences in time and 
supplies attributable to PRINEO* vs. SOC for breast reconstruction in Germany 
(GER) and The Netherlands (NL). METHODS: A time and motion study was con-
ducted in one centre per country with data recorded on Data Observation Forms by 
trained centre staff. In NL, 5 procedures per group were observed involving both 
donor and breast site (DIEAP ﬂap). In GER, 7 SOC and 8 PRINEO* procedures were 
observed involving mostly one site (Latissimus Dorsi). Activities were observed for 
which differences in time and supplies between PRINEO* and SOC were expected: 
incision closure, dressing application, and dressing changes. Analyses were conducted 
for donor and breast combined. RESULTS: In NL, average skin layer closure time 
was 3.19 min for PRINEO* vs. 36.42 min for SOC and speed of closure was higher 
for PRINEO* (31.89 vs. 2.68 cm/min). Including dermal layer closure, total average 
wound closure time was 46.57 min for PRINEO* vs. 68.51 min for SOC, which 
required on average 6.26 min for dressing application and post-op dressing changes 
compared to 3.36 min for PRINEO* removal. In GER, average skin layer closure time 
was 2.98 min for PRINEO* vs. 9.61 min and speed of closure was increased for 
PRINEO* (12.37 vs. 4.05 cm/min). Including dermal layer closure, total average time 
for wound closure was similar (23.29 min vs. 21.73 min). SOC required on average 
13.25 min for dressing application and post-op dressing changes compared to 1.10 min 
for PRINEO* removal. Additionally, average use of 1.13 PRINEO* units (GER) and 
2.00 (NL) resulted in elimination of suture closure materials. CONCLUSIONS: 
PRINEO* lead to increased skin closure speed and avoided time and supplies associ-
ated with dressing application and changes, at the expense of an average at least 1 
PRINEO* unit for donor and breast site combined.
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OBJECTIVES: PRINEO* Skin Closure System (PRINEO*) offers effective and safe 
wound closure compared to Standard of Care (SOC). This study evaluated health 
resource utilization attributable to PRINEO* vs. SOC for breast reduction in Germany 
and the Netherlands. METHODS: A time and motion study was conducted in one 
centre per country. Trained centre staff collected 10 observations in patients who 
